EDISON EQUITY RESEARCH - BELLUS HEALTH
October 06 2014 - 12:52PM
InvestorsHub NewsWire
EDISON EQUITY RESEARCH:
BELLUS HEALTH - AA AMYLOIDOSIS PIVOTAL
STUDY FULLY ENROLLED
Bellus’s lead candidate, Kiacta, recently reached full recruitment
for the pivotal Phase III trial for AA amyloidosis, with data
expected in 2016. We estimate the probability of success at 60%,
given positive efficacy trends in a previous Phase II/III study and
design elements that could raise the likelihood of statistical
separation vs placebo. Bellus’s partner, Auven Therapeutics, is
funding a Phase II Kiacta study in sarcoidosis, to start in Q115.
The potential for premium pricing and extended market exclusivity
drive our C$110m rNPV, which continues to reflect upside even after
Bellus’s share price has more than tripled ytd.
Bellus Health is a Canadian drug development company whose lead
candidate, Kiacta, is in a pivotal Phase III trial for amyloid A
(AA) amyloidosis and is being studied in sarcoidosis. Shigamab is
in preclinical development for Shiga toxin-associated haemolytic
uremic syndrome (STEC-HUS).
To view our full report, please click here:
http://www.edisoninvestmentresearch.com/research/report/bellus-health6
Click here to view all of Edison Investment
Research’s published reports
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Jun 2024 to Jul 2024
Blue Chip Value Fund, Inc. (NYSE:BLU)
Historical Stock Chart
From Jul 2023 to Jul 2024